The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hormone Refractory Breast Cancer Market Research Report 2025
Synopsis
An increasing number of hormone therapies have made refractory breast cancer resistant to treatment, increased incidence of breast cancer, aging population, increased demand for advanced therapies, increased incidence of hormone-refractory breast cancer and the existence of a large number of anti-cancer pipeline drugs, all of which drive the growth of hormone-refractory breast cancer market.
The global Hormone Refractory Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Hormone Refractory Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Hormone Refractory Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Hormone Refractory Breast Cancer in Scientific Research and Production is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Hormone Refractory Breast Cancer include AstraZeneca, AmpliMed Corporation, Roche, Bluefish Pharmaceuticals AB, NeoCorp, Sanofi Genzyme, Neopharm and Boehringer Ingelheim GmbH, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Hormone Refractory Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Refractory Breast Cancer.
Report Scope
The Hormone Refractory Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hormone Refractory Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hormone Refractory Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH
Segment by Type
Tumor Markers Therapy
Gene Expression Therapy
Gene Mutation Therapy
Segment by Application
Scientific Research and Production
Biological Science and Technology
Medical Technology
Medical Apparatus and Instruments
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hormone Refractory Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
An increasing number of hormone therapies have made refractory breast cancer resistant to treatment, increased incidence of breast cancer, aging population, increased demand for advanced therapies, increased incidence of hormone-refractory breast cancer and the existence of a large number of anti-cancer pipeline drugs, all of which drive the growth of hormone-refractory breast cancer market.
The global Hormone Refractory Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Hormone Refractory Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Hormone Refractory Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Hormone Refractory Breast Cancer in Scientific Research and Production is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Hormone Refractory Breast Cancer include AstraZeneca, AmpliMed Corporation, Roche, Bluefish Pharmaceuticals AB, NeoCorp, Sanofi Genzyme, Neopharm and Boehringer Ingelheim GmbH, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Hormone Refractory Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Refractory Breast Cancer.
Report Scope
The Hormone Refractory Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hormone Refractory Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hormone Refractory Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH
Segment by Type
Tumor Markers Therapy
Gene Expression Therapy
Gene Mutation Therapy
Segment by Application
Scientific Research and Production
Biological Science and Technology
Medical Technology
Medical Apparatus and Instruments
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hormone Refractory Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tumor Markers Therapy
1.2.3 Gene Expression Therapy
1.2.4 Gene Mutation Therapy
1.3 Market by Application
1.3.1 Global Hormone Refractory Breast Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Scientific Research and Production
1.3.3 Biological Science and Technology
1.3.4 Medical Technology
1.3.5 Medical Apparatus and Instruments
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hormone Refractory Breast Cancer Market Perspective (2019-2030)
2.2 Hormone Refractory Breast Cancer Growth Trends by Region
2.2.1 Global Hormone Refractory Breast Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hormone Refractory Breast Cancer Historic Market Size by Region (2019-2024)
2.2.3 Hormone Refractory Breast Cancer Forecasted Market Size by Region (2025-2030)
2.3 Hormone Refractory Breast Cancer Market Dynamics
2.3.1 Hormone Refractory Breast Cancer Industry Trends
2.3.2 Hormone Refractory Breast Cancer Market Drivers
2.3.3 Hormone Refractory Breast Cancer Market Challenges
2.3.4 Hormone Refractory Breast Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hormone Refractory Breast Cancer Players by Revenue
3.1.1 Global Top Hormone Refractory Breast Cancer Players by Revenue (2019-2024)
3.1.2 Global Hormone Refractory Breast Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Hormone Refractory Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hormone Refractory Breast Cancer Revenue
3.4 Global Hormone Refractory Breast Cancer Market Concentration Ratio
3.4.1 Global Hormone Refractory Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Breast Cancer Revenue in 2023
3.5 Hormone Refractory Breast Cancer Key Players Head office and Area Served
3.6 Key Players Hormone Refractory Breast Cancer Product Solution and Service
3.7 Date of Enter into Hormone Refractory Breast Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hormone Refractory Breast Cancer Breakdown Data by Type
4.1 Global Hormone Refractory Breast Cancer Historic Market Size by Type (2019-2024)
4.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2025-2030)
5 Hormone Refractory Breast Cancer Breakdown Data by Application
5.1 Global Hormone Refractory Breast Cancer Historic Market Size by Application (2019-2024)
5.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hormone Refractory Breast Cancer Market Size (2019-2030)
6.2 North America Hormone Refractory Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hormone Refractory Breast Cancer Market Size by Country (2019-2024)
6.4 North America Hormone Refractory Breast Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hormone Refractory Breast Cancer Market Size (2019-2030)
7.2 Europe Hormone Refractory Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hormone Refractory Breast Cancer Market Size by Country (2019-2024)
7.4 Europe Hormone Refractory Breast Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hormone Refractory Breast Cancer Market Size (2019-2030)
8.2 Asia-Pacific Hormone Refractory Breast Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hormone Refractory Breast Cancer Market Size (2019-2030)
9.2 Latin America Hormone Refractory Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hormone Refractory Breast Cancer Market Size by Country (2019-2024)
9.4 Latin America Hormone Refractory Breast Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hormone Refractory Breast Cancer Market Size (2019-2030)
10.2 Middle East & Africa Hormone Refractory Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Hormone Refractory Breast Cancer Introduction
11.1.4 AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 AmpliMed Corporation
11.2.1 AmpliMed Corporation Company Detail
11.2.2 AmpliMed Corporation Business Overview
11.2.3 AmpliMed Corporation Hormone Refractory Breast Cancer Introduction
11.2.4 AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.2.5 AmpliMed Corporation Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Hormone Refractory Breast Cancer Introduction
11.3.4 Roche Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.3.5 Roche Recent Development
11.4 Bluefish Pharmaceuticals AB
11.4.1 Bluefish Pharmaceuticals AB Company Detail
11.4.2 Bluefish Pharmaceuticals AB Business Overview
11.4.3 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Introduction
11.4.4 Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.4.5 Bluefish Pharmaceuticals AB Recent Development
11.5 NeoCorp
11.5.1 NeoCorp Company Detail
11.5.2 NeoCorp Business Overview
11.5.3 NeoCorp Hormone Refractory Breast Cancer Introduction
11.5.4 NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.5.5 NeoCorp Recent Development
11.6 Sanofi Genzyme
11.6.1 Sanofi Genzyme Company Detail
11.6.2 Sanofi Genzyme Business Overview
11.6.3 Sanofi Genzyme Hormone Refractory Breast Cancer Introduction
11.6.4 Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.6.5 Sanofi Genzyme Recent Development
11.7 Neopharm
11.7.1 Neopharm Company Detail
11.7.2 Neopharm Business Overview
11.7.3 Neopharm Hormone Refractory Breast Cancer Introduction
11.7.4 Neopharm Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.7.5 Neopharm Recent Development
11.8 Boehringer Ingelheim GmbH
11.8.1 Boehringer Ingelheim GmbH Company Detail
11.8.2 Boehringer Ingelheim GmbH Business Overview
11.8.3 Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Introduction
11.8.4 Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2019-2024)
11.8.5 Boehringer Ingelheim GmbH Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
